Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BridgeBio Pharma, Inc.BBIO · Entity 3360 | Chief Scientific Officer | December 15, 2020 | December 17, 2020 |
| PROKIDNEY CORP.PROK · Entity 5181 | Director | May 28, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BridgeBio Pharma, Inc.
Report date December 15, 2020 · Filed December 17, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.07 · Expires 2030-04-01 | Direct | 8,912 |
Reported balance
After 2020-12-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-12-15 · Grant · Acquired 8,912 · Balance 8,912 F1: The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in a privately-held subsidiary of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio. F2: 3,342 shares subject to the stock option were vested as of the date of acquisition, 186 shares shall vest on January 1, 2021, and 5,384 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.07 · Expires 2030-07-20 | Direct | 10,832 |
Reported balance
After 2020-12-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-12-15 · Grant · Acquired 10,832 · Balance 10,832 F1: The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in a privately-held subsidiary of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio. F3: 4,062 shares subject to the stock option were vested as of the date of acquisition, 226 shares shall vest on January 1, 2021, and 6,544 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.80 · Expires 2030-09-29 | Direct | 5,717 |
Reported balance
After 2020-12-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-12-15 · Grant · Acquired 5,717 · Balance 5,717 F1: The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in a privately-held subsidiary of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio. F4: 2,144 shares subject to the stock option were vested as of the date of acquisition, 119 shares shall vest on January 1, 2021, and 3,454 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in a privately-held subsidiary of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio.
F2: 3,342 shares subject to the stock option were vested as of the date of acquisition, 186 shares shall vest on January 1, 2021, and 5,384 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date.
F3: 4,062 shares subject to the stock option were vested as of the date of acquisition, 226 shares shall vest on January 1, 2021, and 6,544 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date.
F4: 2,144 shares subject to the stock option were vested as of the date of acquisition, 119 shares shall vest on January 1, 2021, and 3,454 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date.
PROKIDNEY CORP.
Report date May 28, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.81 · Expires 2036-05-28 | Direct | 135,000 |
Reported balance
After 2026-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-28 · Grant · Acquired 135,000 · Balance 135,000 F1: These options were granted under the Issuer's non-employee director compensation policy. F2: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: These options were granted under the Issuer's non-employee director compensation policy.
F2: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Eidos Therapeutics, Inc.
Report date January 26, 2021 · Filed January 29, 2021
Section 16 reporting ended · disclosed 2021-01-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2021-01-26 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-10-27 · Gift · Disposed 3,000 · Balance 303,525 Row 2 · 2021-01-26 · Other · Disposed 303,525 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger dated October 5, 2020 (the "Merger Agreement"), by and among the Issuer, BridgeBio Pharma, Inc. ("Parent"), Globe Merger Sub 1, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), and Globe Merger Sub II, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub II"), Merger Sub was merged with and into the Issuer, with the Issuer continuing as the surviving corporation and immediately thereafter, the Issuer was merged with and into Merger Sub II, with Merger Sub II continuing as the surviving corporation, effective as of January 26, 2021 (the "Effective Time"). At the Effective Time, each shares of Issuer common stock that was outstanding and held by the Reporting Person immediately prior to the Effective Time was cancelled and automatically converted into 1.85 shares of Parent common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.20 · Expires 2028-11-05 | Direct | 0 |
Reported balance
After 2021-01-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-01-26 · Disposition to issuer · Disposed 60,000 · Balance 0 F2: The option vests over four years after November 5, 2018. At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger dated October 5, 2020 (the "Merger Agreement"), by and among the Issuer, BridgeBio Pharma, Inc. ("Parent"), Globe Merger Sub 1, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), and Globe Merger Sub II, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub II"), Merger Sub was merged with and into the Issuer, with the Issuer continuing as the surviving corporation and immediately thereafter, the Issuer was merged with and into Merger Sub II, with Merger Sub II continuing as the surviving corporation, effective as of January 26, 2021 (the "Effective Time"). At the Effective Time, each shares of Issuer common stock that was outstanding and held by the Reporting Person immediately prior to the Effective Time was cancelled and automatically converted into 1.85 shares of Parent common stock.
F2: The option vests over four years after November 5, 2018. At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 28, 2026 Filed May 29, 2026 20:04 UTC | PROKIDNEY CORP. PROK · Entity 5181 | GrantDirector stock option (right to buy) · Derivative | 135,000 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0001193125-26-248226 · ownership.xml · derivative · entry 1 Sinha Uma · CIK 0001742587 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,000 Underlying: Class A Common Stock · 135,000 shares Expires 2036-05-28 F1 · shares: These options were granted under the Issuer's non-employee director compensation policy. F2 · derivative.exercise_date: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:14 UTC | PROKIDNEY CORP. PROK · Entity 5181 | GrantDirector stock option (right to buy) · Derivative | 125,862 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0000950170-25-080272 · ownership.xml · derivative · entry 1 Sinha Uma · CIK 0001742587 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,862 Underlying: Class A Ordinary Shares · 125,862 shares Expires 2035-05-29 F1 · shares: These options were granted under the Issuer's non-employee director compensation policy. F2 · derivative.exercise_date: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 20:34 UTC | PROKIDNEY CORP. PROK · Entity 5181 | GrantDirector stock option (right to buy) · Derivative | 62,558 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0000950170-24-068047 · ownership.xml · derivative · entry 1 Sinha Uma · CIK 0001742587 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,558 Underlying: Class A Ordinary Shares · 62,558 shares Expires 2034-05-30 F1 · shares: These options were granted under the Issuer's non-employee director compensation policy. F2 · derivative.exercise_date: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting. Read SEC document |
| June 29, 2023 Filed Jul 3, 2023 13:18 UTC | PROKIDNEY CORP. PROK · Entity 5181 | GrantDirector stock option (right to buy) · Derivative | 48,128 | $0.00 Strike: $10.56 | $0.00 |
DisclosureSEC source: 0001209191-23-040425 · doc4.xml · derivative · entry 1 Sinha Uma · CIK 0001742587 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,128 Underlying: Class A Ordinary Shares · 48,128 shares Expires 2033-06-29 F1 · shares: These options were granted under the Issuer's non-employee director compensation policy. F2 · derivative.exercise_date: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting. Read SEC document |
| July 11, 2022 Filed Jul 14, 2022 01:28 UTC | PROKIDNEY CORP. PROK · Entity 5181 | GrantClass A Ordinary Shares | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-22-012368 · dp177039_4-sinha.xml · nonDerivative · entry 1 Sinha Uma · CIK 0001742587 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · shares: Represents a grant of 30,000 restricted stock units that vested in full on July 11, 2022 and will settle in Class A Ordinary Shares on a date selected by the issuer between the vesting date and March 15, 2023. Read SEC document |
| January 26, 2021 Filed Jan 29, 2021 00:00 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | Disposition to issuerStock Option (Right to Buy) · Derivative | 60,000 | Not disclosed Strike: $13.20 | Not disclosed |
DisclosureSEC source: 0000899243-21-003639 · doc4.xml · derivative · entry 3 Sinha Uma · CIK 0001742587 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2028-11-05 F2 · price: The option vests over four years after November 5, 2018. At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time. F2 · derivative.exercise_date: The option vests over four years after November 5, 2018. At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time. Read SEC document |
| January 26, 2021 Filed Jan 29, 2021 00:00 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | OtherCommon Stock | 303,525 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-003639 · doc4.xml · nonDerivative · entry 2 Sinha Uma · CIK 0001742587 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the terms of the Agreement and Plan of Merger dated October 5, 2020 (the "Merger Agreement"), by and among the Issuer, BridgeBio Pharma, Inc. ("Parent"), Globe Merger Sub 1, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), and Globe Merger Sub II, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub II"), Merger Sub was merged with and into the Issuer, with the Issuer continuing as the surviving corporation and immediately thereafter, the Issuer was merged with and into Merger Sub II, with Merger Sub II continuing as the surviving corporation, effective as of January 26, 2021 (the "Effective Time"). At the Effective Time, each shares of Issuer common stock that was outstanding and held by the Reporting Person immediately prior to the Effective Time was cancelled and automatically converted into 1.85 shares of Parent common stock. F1 · price: Pursuant to the terms of the Agreement and Plan of Merger dated October 5, 2020 (the "Merger Agreement"), by and among the Issuer, BridgeBio Pharma, Inc. ("Parent"), Globe Merger Sub 1, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), and Globe Merger Sub II, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub II"), Merger Sub was merged with and into the Issuer, with the Issuer continuing as the surviving corporation and immediately thereafter, the Issuer was merged with and into Merger Sub II, with Merger Sub II continuing as the surviving corporation, effective as of January 26, 2021 (the "Effective Time"). At the Effective Time, each shares of Issuer common stock that was outstanding and held by the Reporting Person immediately prior to the Effective Time was cancelled and automatically converted into 1.85 shares of Parent common stock. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:05 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 300 | $126.39 | $37,917.00 |
DisclosureSEC source: 0000899243-21-002179 · doc4.xml · nonDerivative · entry 6 Sinha Uma · CIK 0001742587 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 306,525 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on August 13, 2020. F7 · price: Represents the weighted average sale price of the shares sold ranging from $126.30 to $126.57 per share. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:05 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 2,000 | $125.35 | $250,700.00 |
DisclosureSEC source: 0000899243-21-002179 · doc4.xml · nonDerivative · entry 5 Sinha Uma · CIK 0001742587 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 306,825 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on August 13, 2020. F6 · price: Represents the weighted average sale price of the shares sold ranging from $125.11 to $125.66 per share. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:05 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 4,934 | $124.72 | $615,362.07 |
DisclosureSEC source: 0000899243-21-002179 · doc4.xml · nonDerivative · entry 4 Sinha Uma · CIK 0001742587 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,825 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on August 13, 2020. F5 · price: Represents the weighted average sale price of the shares sold ranging from $124.10 to $125.09 per share. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:05 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 1,498 | $123.48 | $184,971.09 |
DisclosureSEC source: 0000899243-21-002179 · doc4.xml · nonDerivative · entry 3 Sinha Uma · CIK 0001742587 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,759 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on August 13, 2020. F4 · price: Represents the weighted average sale price of the shares sold ranging from $123.01 to $124.00 per share. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:05 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 572 | $122.27 | $69,936.55 |
DisclosureSEC source: 0000899243-21-002179 · doc4.xml · nonDerivative · entry 2 Sinha Uma · CIK 0001742587 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,257 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on August 13, 2020. F3 · price: Represents the weighted average sale price of the shares sold ranging from $121.98 to $122.89 per share. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:05 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 696 | $121.11 | $84,292.14 |
DisclosureSEC source: 0000899243-21-002179 · doc4.xml · nonDerivative · entry 1 Sinha Uma · CIK 0001742587 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,829 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on August 13, 2020. F2 · price: Represents the weighted average sale price of the shares sold ranging from $120.81 to $121.33 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 7. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 21:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (Right to Buy) · Derivative | 5,717 | $0.00 Strike: $42.80 | $0.00 |
DisclosureSEC source: 0000899243-20-034284 · doc4.xml · derivative · entry 3 Sinha Uma · CIK 0001742587 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,717 Underlying: Common Stock · 5,717 shares Expires 2030-09-29 F1 · kind: The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in a privately-held subsidiary of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio. F4 · derivative.exercise_date: 2,144 shares subject to the stock option were vested as of the date of acquisition, 119 shares shall vest on January 1, 2021, and 3,454 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 21:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (Right to Buy) · Derivative | 10,832 | $0.00 Strike: $3.07 | $0.00 |
DisclosureSEC source: 0000899243-20-034284 · doc4.xml · derivative · entry 2 Sinha Uma · CIK 0001742587 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,832 Underlying: Common Stock · 10,832 shares Expires 2030-07-20 F1 · kind: The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in a privately-held subsidiary of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio. F3 · derivative.exercise_date: 4,062 shares subject to the stock option were vested as of the date of acquisition, 226 shares shall vest on January 1, 2021, and 6,544 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 21:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (Right to Buy) · Derivative | 8,912 | $0.00 Strike: $3.07 | $0.00 |
DisclosureSEC source: 0000899243-20-034284 · doc4.xml · derivative · entry 1 Sinha Uma · CIK 0001742587 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,912 Underlying: Common Stock · 8,912 shares Expires 2030-04-01 F1 · kind: The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in a privately-held subsidiary of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio. F2 · derivative.exercise_date: 3,342 shares subject to the stock option were vested as of the date of acquisition, 186 shares shall vest on January 1, 2021, and 5,384 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date. Read SEC document |
| December 02, 2020 Filed Dec 4, 2020 22:34 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 200 | $92.97 | $18,593.00 |
DisclosureSEC source: 0000899243-20-032771 · doc4.xml · nonDerivative · entry 4 Sinha Uma · CIK 0001742587 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,525 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on August 13, 2020. F5 · price: Represents the weighted average sale price of the shares sold ranging from $92.71 to $93.22 per share. Read SEC document |
| December 02, 2020 Filed Dec 4, 2020 22:34 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 300 | $91.89 | $27,567.00 |
DisclosureSEC source: 0000899243-20-032771 · doc4.xml · nonDerivative · entry 3 Sinha Uma · CIK 0001742587 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,725 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on August 13, 2020. F4 · price: Represents the weighted average sale price of the shares sold ranging from $91.56 to $92.10 per share. Read SEC document |
| December 02, 2020 Filed Dec 4, 2020 22:34 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 702 | $90.63 | $63,625.00 |
DisclosureSEC source: 0000899243-20-032771 · doc4.xml · nonDerivative · entry 2 Sinha Uma · CIK 0001742587 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,025 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on August 13, 2020. F3 · price: Represents the weighted average sale price of the shares sold ranging from $90.33 to $91.18 per share. Read SEC document |
| December 02, 2020 Filed Dec 4, 2020 22:34 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 3,798 | $89.63 | $340,402.21 |
DisclosureSEC source: 0000899243-20-032771 · doc4.xml · nonDerivative · entry 1 Sinha Uma · CIK 0001742587 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,727 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on August 13, 2020. F2 · price: Represents the weighted average sale price of the shares sold ranging from $89.15 to $90.125 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 5. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 00:39 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 469 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-031549 · doc4.xml · derivative · entry 2 Sinha Uma · CIK 0001742587 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,563 Underlying: Common Stock · 469 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs vest over approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date. 6.25% of the RSUs vested on August 16, 2020 and November 16, 2020 and an additional 6.25% will vest in quarterly installments on the 16th day of each February, May, August and November thereafter, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. F2 · derivative.expiration_date: The RSUs vest over approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date. 6.25% of the RSUs vested on August 16, 2020 and November 16, 2020 and an additional 6.25% will vest in quarterly installments on the 16th day of each February, May, August and November thereafter, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 00:39 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 469 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-031549 · doc4.xml · nonDerivative · entry 1 Sinha Uma · CIK 0001742587 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,460 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| October 29, 2020 Filed Oct 30, 2020 20:55 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 3,700 | $72.60 | $268,625.92 |
DisclosureSEC source: 0000899243-20-029938 · doc4.xml · nonDerivative · entry 2 Sinha Uma · CIK 0001742587 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,525 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on August 13, 2020. F3 · price: Represents the weighted average sale price of the shares sold ranging from $72.29 to $72.94 per share. Read SEC document |
| October 29, 2020 Filed Oct 30, 2020 20:55 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 1,300 | $71.90 | $93,473.12 |
DisclosureSEC source: 0000899243-20-029938 · doc4.xml · nonDerivative · entry 1 Sinha Uma · CIK 0001742587 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,225 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on August 13, 2020. F2 · price: Represents the weighted average sale price of the shares sold ranging from $71.26 to $72.23 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3. Read SEC document |
| October 27, 2020 Filed Jan 29, 2021 00:00 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | GiftCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-003639 · doc4.xml · nonDerivative · entry 1 Sinha Uma · CIK 0001742587 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303,525 Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 23:43 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 4,831 | $52.35 | $252,923.14 |
DisclosureSEC source: 0000899243-20-026974 · doc4.xml · nonDerivative · entry 3 Sinha Uma · CIK 0001742587 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,525 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on August 13, 2020. F2 · price: Represents the weighted average sale price of the shares sold ranging from $52.05 to $53.00 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 23:43 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 100 | $52.00 | $5,200.00 |
DisclosureSEC source: 0000899243-20-026974 · doc4.xml · nonDerivative · entry 2 Sinha Uma · CIK 0001742587 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,356 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on August 13, 2020. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 23:43 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 69 | $52.08 | $3,593.52 |
DisclosureSEC source: 0000899243-20-026974 · doc4.xml · nonDerivative · entry 1 Sinha Uma · CIK 0001742587 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,456 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on August 13, 2020. Read SEC document |
| August 16, 2020 Filed Aug 18, 2020 23:03 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 468 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-022792 · doc4.xml · derivative · entry 2 Sinha Uma · CIK 0001742587 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,032 Underlying: Common Stock · 468 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs vest over approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date. 6.25% of the RSUs vested on August 16, 2020 and an additional 6.25% will vest in quarterly installments on the 16th day of each February, May, August and November thereafter, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. F2 · derivative.expiration_date: The RSUs vest over approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date. 6.25% of the RSUs vested on August 16, 2020 and an additional 6.25% will vest in quarterly installments on the 16th day of each February, May, August and November thereafter, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. Read SEC document |
| August 16, 2020 Filed Aug 18, 2020 23:03 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 468 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-022792 · doc4.xml · nonDerivative · entry 1 Sinha Uma · CIK 0001742587 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,991 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:07 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantRestricted Stock Units · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-015047 · doc4.xml · derivative · entry 1 Sinha Uma · CIK 0001742587 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs will vest approximately four years with a vesting commencement date of May 16, 2020. 6.25% of the RSUs will vest on August 16, 2020 and an additional 6.25% will vest in quarterly installments thereafter, subject to continued service with the Issuer or any of its subsidiaries through each applicable vesting date. F2 · derivative.expiration_date: The RSUs will vest approximately four years with a vesting commencement date of May 16, 2020. 6.25% of the RSUs will vest on August 16, 2020 and an additional 6.25% will vest in quarterly installments thereafter, subject to continued service with the Issuer or any of its subsidiaries through each applicable vesting date. Read SEC document |
| May 31, 2020 Filed Jun 5, 2020 20:05 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | GrantCommon Stock | 444 | $41.57 | $18,458.63 |
DisclosureSEC source: 0000899243-20-015410 · doc4.xml · nonDerivative · entry 1 Sinha Uma · CIK 0001742587 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,525 F1 · kind: Shares acquired pursuant to the Issuer's 2018 Employee Stock Purchase Plan. Read SEC document |
| May 19, 2020 Filed May 21, 2020 20:18 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (Right to Buy) · Derivative | 3,022 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0000899243-20-013835 · doc4.xml · derivative · entry 5 Sinha Uma · CIK 0001742587 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,022 Underlying: Common Stock · 3,022 shares Expires 2029-09-30 F2 · kind: The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in Subsidiaries of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio. Read SEC document |
| May 19, 2020 Filed May 21, 2020 20:18 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (Right to Buy) · Derivative | 49,765 | $0.00 Strike: $0.34 | $0.00 |
DisclosureSEC source: 0000899243-20-013835 · doc4.xml · derivative · entry 4 Sinha Uma · CIK 0001742587 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,765 Underlying: Common Stock · 49,765 shares Expires 2029-07-14 F2 · kind: The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in Subsidiaries of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio. F4 · derivative.exercise_date: 25,134 shares subject to the stock option were vested and exercisable as of the date of acquisition, 1,571 shares shall vest and become exercisable on June 1, 2020, and 23,060 shares shall vest and become exercisable in monthly installments over the next 15 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date. Read SEC document |
| May 19, 2020 Filed May 21, 2020 20:18 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (Right to Buy) · Derivative | 49,361 | $0.00 Strike: $0.16 | $0.00 |
DisclosureSEC source: 0000899243-20-013835 · doc4.xml · derivative · entry 3 Sinha Uma · CIK 0001742587 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,361 Underlying: Common Stock · 49,361 shares Expires 2029-05-23 F2 · kind: The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in Subsidiaries of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio. F3 · derivative.exercise_date: 24,930 shares subject to the stock option were vested and exercisable as of the date of acquisition, 1,558 shares shall vest and become exercisable on June 1, 2020, and 22,873 shares shall vest and become exercisable in monthly installments over the next 15 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date. Read SEC document |
| May 19, 2020 Filed May 21, 2020 20:18 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (Right to Buy) · Derivative | 5,366 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0000899243-20-013835 · doc4.xml · derivative · entry 2 Sinha Uma · CIK 0001742587 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,366 Underlying: Common Stock · 5,366 shares Expires 2027-11-15 F2 · kind: The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in Subsidiaries of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio. Read SEC document |
| May 19, 2020 Filed May 21, 2020 20:18 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantCommon Stock | 1,523 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-013835 · doc4.xml · nonDerivative · entry 1 Sinha Uma · CIK 0001742587 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,523 F1 · kind: The shares were acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in privately-held subsidiaries of the Issuer (each, a "Subsidiary" and collectively, the "Subsidiaries"). Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:32 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 1,702 | $63.31 | $107,760.60 |
DisclosureSEC source: 0000899243-19-029765 · doc4.xml · nonDerivative · entry 3 Sinha Uma · CIK 0001742587 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,081 F3 · price: Represents the weighted average sale price of the shares sold from $63.10 to $63.785 per share. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:32 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 825 | $62.49 | $51,552.52 |
DisclosureSEC source: 0000899243-19-029765 · doc4.xml · nonDerivative · entry 2 Sinha Uma · CIK 0001742587 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,783 F2 · price: Represents the weighted average sale price of the shares sold from $62.08 to $63.075 per share Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:32 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 9,973 | $61.61 | $614,480.41 |
DisclosureSEC source: 0000899243-19-029765 · doc4.xml · nonDerivative · entry 1 Sinha Uma · CIK 0001742587 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,608 F1 · price: Represents the weighted average sale price of the shares sold from $61.085 to $62.075 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all sales reported in footnotes 1 through 3. Read SEC document |
| September 25, 2019 Filed Sep 27, 2019 20:05 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 100 | $39.15 | $3,915.00 |
DisclosureSEC source: 0000899243-19-024339 · doc4.xml · nonDerivative · entry 2 Sinha Uma · CIK 0001742587 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 343,581 Read SEC document |
| September 25, 2019 Filed Sep 27, 2019 20:05 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 2,400 | $38.38 | $92,101.44 |
DisclosureSEC source: 0000899243-19-024339 · doc4.xml · nonDerivative · entry 1 Sinha Uma · CIK 0001742587 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 343,681 F1 · price: Represents the weighted average sale price of the shares sold from $37.94 to $38.80 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 25, 2019 Filed Jul 29, 2019 20:05 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 33 | $38.35 | $1,265.55 |
DisclosureSEC source: 0000899243-19-020520 · doc4.xml · nonDerivative · entry 5 Sinha Uma · CIK 0001742587 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 346,081 Read SEC document |
| July 25, 2019 Filed Jul 29, 2019 20:05 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 700 | $37.31 | $26,117.00 |
DisclosureSEC source: 0000899243-19-020520 · doc4.xml · nonDerivative · entry 4 Sinha Uma · CIK 0001742587 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 346,114 F4 · price: Represents the weighted average sale price of the shares sold from $37.11 to $37.45 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 25, 2019 Filed Jul 29, 2019 20:05 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 1,300 | $36.53 | $47,484.97 |
DisclosureSEC source: 0000899243-19-020520 · doc4.xml · nonDerivative · entry 3 Sinha Uma · CIK 0001742587 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 346,814 F3 · price: Represents the weighted average sale price of the shares sold from $36.08 to $37.05 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 25, 2019 Filed Jul 29, 2019 20:05 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 2,967 | $35.65 | $105,759.61 |
DisclosureSEC source: 0000899243-19-020520 · doc4.xml · nonDerivative · entry 2 Sinha Uma · CIK 0001742587 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 348,114 F2 · price: Represents the weighted average sale price of the shares sold from $35.07 to $36.06 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:17 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | PurchaseCommon Stock | 14,000 | $17.00 | $238,000.00 |
DisclosureSEC source: 0000899243-19-019150 · doc4.xml · nonDerivative · entry 1 Sinha Uma · CIK 0001742587 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Read SEC document |
| May 31, 2019 Filed Jul 29, 2019 20:05 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | GrantCommon Stock | 1,769 | $12.01 | $21,246.57 |
DisclosureSEC source: 0000899243-19-020520 · doc4.xml · nonDerivative · entry 1 Sinha Uma · CIK 0001742587 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 351,081 F1 · kind: Shares acquired pursuant to the Issuer's 2018 Employee Stock Purchase Plan. Read SEC document |
| May 23, 2019 Filed May 28, 2019 20:01 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 800 | $27.88 | $22,304.00 |
DisclosureSEC source: 0000899243-19-014838 · doc4.xml · nonDerivative · entry 3 Sinha Uma · CIK 0001742587 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349,312 F3 · price: Represents the weighted average sale price of the shares sold ranging from $27.55 to $28.43 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 23, 2019 Filed May 28, 2019 20:01 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 4,200 | $27.16 | $114,072.00 |
DisclosureSEC source: 0000899243-19-014838 · doc4.xml · nonDerivative · entry 2 Sinha Uma · CIK 0001742587 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,112 F2 · price: Represents the weighted average sale price of the shares sold ranging from $26.52 to $27.51 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.